

Supplementary Table 1. Detection of HR HPV and genotypes in fine needle aspirates (FNA) and tumor tissue stained for p16 antigens from 40 Patients with Primary Tonsillar Tumors. ^aAptima E6/E7 mRNA assays; ^bcobas 4800 HPV DNA assay; ^cp16 immunohistochemical stain of formalin-fixed paraffin-embedded tissue; ^dNon-16 or 18/45 HR HPV genotypes; ^eHPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68; ^fISV-Insufficient volume; ^gINV-invalid; ^hND - not done.

Patient ID	FNA		Tumor Tissue		
	mRNA ^a	DNA ^b	p16 ^c	mRNA ^a	DNA ^b
8	-	-	+	+ other ^d	+other ^e
13	16	16	+	16	16
17	16	16	+	16	16
18	16	16	+	16	16
19	16	16	+	16	16
24	16	16	+	16	16
35	16	16	+	-	-
37	16	16	+	16	16
44	16	16	+	16	16
45	16	16	+	16	16
50	16	16	+	16	16
51	-	16	+	+ other ^d	16
58	-	-	+	+ other ^d	+other ^e
67	16	16	+	16	16
77	16	16	+	16	16
78	16	16	+	16	16
79	16	16	+	16	16
10	+ other ^d	+ other ^e	+	ND ^h	ND ^h
14	16	16	+	ND ^h	ND ^h
21	16	16	+	ND ^h	ND ^h
30	16	16	+	ND ^h	ND ^h
38	-	-	+	ND ^h	ND ^h
41	16	ISV ^f	+	ND ^h	ND ^h
46	16	16	+	ND ^h	ND ^h
49	16	16	+	ND ^h	ND ^h
56	-	INV ^g	+	ND ^h	ND ^h
60	16	-	+	ND ^h	ND ^h
61	16	16	+	ND ^h	ND ^h
62	16	16	+	ND ^h	ND ^h
80	16	16	+	ND ^h	ND ^h
81	16	ISV ^f	+	ND ^h	ND ^h
91	16	16	-	16	16
59	-	-	-	-	-
85	-	-	-	-	-
22	-	-	-	ND ^h	ND ^h
23	-	16	-	ND ^h	ND ^h
31	-	-	-	ND ^h	ND ^h
54	-	-	-	ND ^h	ND ^h
57	-	-	-	ND ^h	ND ^h
89	-	ISV ^f	-	ND ^h	ND ^h
TOTAL	67.50%	72.20%	77.50%	85% (17/20)	85% (17/20)
	(27/40)	(26/36)	(31/40)		

Supplemental Table 2. Detection of HR HPV and genotypes in fine needle aspirates (FNA) and tumor tissue stained for p16 antigens from 30 Patients with Primary Base of Tongue Tumors. ^aAptima E6/E7 mRNA assays; ^bcobas 4800 HPV DNA assay; ^cp16 immunohistochemical stain of formalin-fixed paraffin-embedded tissue; ^dHPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68; ^eNon-16 or 18/45 HR HPV genotypes; ^fISV-Insufficient volume; ^gINV-invalid; ^hND - not done.

Patient ID	FNA		Tumour Tissue		
	mRNA ^a	DNA ^b	p16 ^c	mRNA ^a	DNA ^b
4	16	16	+	16	16
7	-	-	+	16	16
32	16	16	+	16	16
33	0.4	+ other ^d	+	+other ^e	+16/other ^d
39	-	-	+	16	16
47	16	16	+	16	16
52	16	16	+	16	16
64	16	ISV ^f	+	16	16
72	-	-	+	16	16
87	16	16	+	16	16
88	-	-	+	16	16
90	16	16	+	16	16
2	16	16	+	ND ^h	ND ^h
11	16	16	+	ND ^h	ND ^h
15	16	INV ^g	+	ND ^h	ND ^h
20	16	16	+	ND ^h	ND ^h
25	-	-	+	ND ^h	ND ^h
28	16	16	+	ND ^h	ND ^h
29	16	16	+	ND ^h	ND ^h
36	16	16	+	ND ^h	ND ^h
40	16	16	+	ND ^h	ND ^h
43	16	16	+	ND ^h	ND ^h
48	16	16	+	ND ^h	ND ^h
65	16	16	+	ND ^h	ND ^h
75	16	16	+	ND ^h	ND ^h
82	-	-	+	ND ^h	ND ^h
83	16	16	+	ND ^h	ND ^h
86	16	16	+	ND ^h	ND ^h
63	-	16	-	-	-
74	-	-	-	ND ^h	ND ^h
TOTAL	73.30%	75%	93.30%	92.3% (12/13)	92.30%
	(22/30)	(21/28)	(28/30)		(12/13)

Supplemental Table 3. Detection of HR HPV and genotypes in fine needle aspirates (FNA) and tumor tissue stained for p16 antigens from 6 patients with OPSCC at sites other than the base of tongue or tonsils. ^aAptima E6/E7 mRNA assays; ^bcobas 4800 HPV DNA assay; ^cp16 immunohistochemical stain of formalin-fixed paraffin-embedded tissue; ^dND - not done.

Patient ID	Tumour Site	FNA		Tumor Tissue		
		mRNA ^a	DNA ^b	p16 ^c	mRNA ^a	DNA ^b
26	Vallecula	16	16	+	ND ^d	ND ^d
53	Pharyngeal wall	16	16	+	ND ^d	ND ^d
5	Soft palate	16	16	+	ND ^d	ND ^d
6	Soft palate	-	-	-	-	-
66	Soft palate	-	-	-	-	-
68	Soft palate	-	-	-	ND ^d	ND ^d
TOTAL		50% (3/6)	50% (3/6)	50% (3/6)	(0/6)	(0/6)